What is Zacks Research’s Estimate for TSE:BHC Q3 Earnings?

Bausch Health Companies Inc. (TSE:BHC) – Analysts at Zacks Research decreased their Q3 2026 earnings estimates for Bausch Health Companies in a report issued on Wednesday, August 19th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.44 for the quarter, down from their prior estimate of $1.47. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.61 EPS, Q2 2027 earnings at $1.27 EPS, Q3 2027 earnings at $1.49 EPS, Q4 2027 earnings at $1.41 EPS, FY2027 earnings at $5.33 EPS, Q1 2028 earnings at $0.91 EPS and Q2 2028 earnings at $1.19 EPS.

Bausch Health Companies (TSE:BHC) last released its earnings results on Wednesday, July 29th. The company reported C$1.79 earnings per share for the quarter. Bausch Health Companies had a negative net margin of 12.02% and a positive return on equity of 87.57%. The firm had revenue of C$4.05 billion for the quarter.

Separately, Jefferies Financial Group upgraded Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 22nd. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Bausch Health Companies Trading Down 0.7%

Shares of BHC stock opened at C$9.41 on Friday. The company has a quick ratio of 0.58, a current ratio of 1.44 and a debt-to-equity ratio of -1,173.29. The firm has a market cap of C$3.52 billion, a P/E ratio of -3.20, a PEG ratio of 0.21 and a beta of 0.96. The company has a 50 day moving average of C$7.49 and a 200-day moving average of C$7.56. Bausch Health Companies has a 12-month low of C$6.10 and a 12-month high of C$11.08.

Trending Headlines about Bausch Health Companies

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Zacks raised its FY2026 EPS estimate to $5.88 from $5.54, above the current consensus estimate of $5.55. The firm also increased its FY2027 forecast to $5.33 from $5.06.
• Positive Sentiment: Several quarterly estimates were upgraded, including Q1 2027 EPS to $1.17 from $1.13, Q2 2027 EPS to $1.27 from $1.15, Q3 2027 EPS to $1.49 from $1.46, and Q4 2027 EPS to $1.41 from $1.32.
• Positive Sentiment: Zacks also raised its longer-dated estimates for Q1 2028 EPS to $0.91 from $0.81 and Q2 2028 EPS to $1.19 from $1.14, suggesting improved expectations for earnings in portions of 2027 and 2028.
• Neutral Sentiment: The revisions leave Zacks’ current full-year consensus reference at approximately $5.55 EPS, while the firm’s FY2027 estimate of $5.33 remains below that level.
• Negative Sentiment: Zacks lowered its Q3 2026 EPS forecast to $1.44 from $1.47 and reduced its Q4 2026 estimate to $1.61 from $1.62. It also trimmed FY2028 EPS to $4.22 from $4.26.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.